Glenmark Pharmaceuticals Inc., USA recalls chlorproMAZINE…
Glenmark Pharmaceuticals Inc., USA recalls chlorproMAZINE Hydrochloride Tablets
- Published
- 9 Apr 2025
- Units affected
- 8160 bottles
- Agency
- FDA
- Country
- United States
The hazard
CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.
Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What to do
Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.
- Check the lot number on the box or bottle.
- Talk to your pharmacist or doctor before stopping any prescribed medicine.
- Return the product to the pharmacy for safe disposal.
Product details
chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-01
- Brand / company
- Glenmark Pharmaceuticals Inc., USA
- Codes / lots
- Lot#s: 17232222 and 17232237, Exp 10/31/2025
- Distribution
- Nationwide in the USA and PR
- Recall status
- Ongoing
Source: U.S. Food and Drug Administration, published 9 Apr 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.